Clinical trial NCT01253421: The Effects of Dopamine on Reward Processing
Official title: The Effects of Dopamine on Reward Processing
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Major Depressive Disorder (MDD)
Keywords: MDD
Major Depressive Disorder
Amisulpride
Lead sponsor: Mclean Hospital
Sponsor class: OTHER
Collaborators: name: National Institute of Mental Health (NIMH)
First posted: 2010-12-03
Enrollment: 159
Sex: ALL
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: There were two groups of subjects: currently experiencing a major depressive episode, or normal health controls. The groups were matched for age, gender, and race. Within each group, half of the subjects were assigned to receive the study drug (amisulpride) and half to receive a placebo.
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the effects of a single low dose of the D2/D3 antagonist amisulpride on reward processing. More generally, this study will test the role of dopamine (a naturally occurring brain chemical) in depression.

Hypotheses:

Administration of a single low dose of the D2/D3 antagonist amisulpride will (1) improve performance in a behavioral task assessing learning from feedback and (2) boost activation in reward-related brain regions.

Detailed description: Through an integration of a functional magnetic resonance imaging (fMRI) approach coupled with a pharmacological challenge, the goal of the current study will be to investigate the role of dopamine in MDD. Participants in this research will include 36 MDD subjects and 36 demographically matched healthy participants recruited from the community by Dr. Pizzagalli's laboratory at McLean Hospital's Center for Depression, Anxiety and Stress Research. This study will include two sessions:

* The first session will involve a diagnostic interview, and a series of questionnaires and assessments.
* The second session will take place at the McLean Hospital's Neuroimaging Center, and include the administration of a low-dose of amisulpride (50 mg capsule) or placebo, followed by an fMRI brain scan and administration of two behavioral tasks.

Eligibility criteria: Inclusion Criteria:

* Inclusion Criteria for subjects with Major Depressive Disorder (MDD):

  1. Diagnostic and Statistical Manual of Mental Disorders (DSM IV) diagnostic criteria for MDD, diagnosed with the use of the Structured Clinical Interview for DSM Disorders (SCID);
  2. Written informed consent;
  3. Both genders and all ethnic origins, age between 18 and 45;
  4. A baseline score \> 16 on the Hamilton Rating Scale for Depression (HRSD) 17-item version;
  5. Right-handed.
  6. Absence of any psychotropic medications for at least 2 weeks:

     * 6 weeks for fluoxetine,
     * 6 months for neuroleptics,
     * 2 weeks for benzodiazepines,
     * 2 weeks for any other antidepressants.

Inclusion Criteria for Control Subjects:

1. Absence of medical, neurological, and psychiatric illness (including alcohol and substance abuse), as assessed by subject history and a structured clinical interview (SCID-I/NP);
2. Written informed consent;
3. Both genders and all ethnic origins, age between 18 and 45;
4. Right-handed;
5. Absence of any medications for at least 3 weeks;
6. Absence of pregnancy.

Exclusion Criteria:

* Exclusion Criteria for All Subjects:

  1. Subjects with suicidal ideation where outpatient treatment is determined unsafe by the study clinician. These patients will be immediately referred to appropriate clinical treatment;
  2. Pregnant women or women of childbearing potential who are not using a medically accepted means of contraception (defined as oral contraceptive pill or implant, condom, diaphragm, spermicide, intrauterine device, s/p tubal ligation, or partner with vasectomy);
  3. Serious or unstable medical illness, including cardiovascular, hepatic, renal, respiratory, endocrine, neurological or hematologic disease;
  4. Lifetime history of seizure disorder;
  5. Lifetime history or current diagnosis of any of the following DSM-IV psychiatric illnesses: organic mental disorder, schizophrenia, schizoaffective disorder, delusional disorder, psychotic disorders not otherwise specified, bipolar disorder, patients with mood congruent or mood incongruent psychotic features, substance dependence, substance abuse within the last 12 months (with the exception of alcohol abuse within the last 12 months, which is permissible for MDD subjects); eating disorders, post-traumatic stress disorder (lifetime PTSD is exclusionary for control subjects, PTSD within the last 24 months is exclusionary for MDD subjects); simple phobia, social anxiety disorder and generalized anxiety disorders will be allowed only if secondary to MDD;
  6. More than five instances of lifetime cocaine or stimulant use (e.g., amphetamine, cocaine, methamphetamine);
  7. Use of dopaminergic drugs (including methylphenidate) within the last 6 months;
  8. Lifetime history or current diagnosis of dementia, or a score of \< 26 on the Mini Mental Status Examination at the screening visit;
  9. Lifetime history of adverse drug reactions or allergy to the study drug (amisulpride);
  10. Patients with mood congruent or mood incongruent psychotic features;
  11. Current use of other psychotropic drugs;
  12. Clinical or laboratory evidence of hypothyroidism;
  13. Patients with a lifetime history of electroconvulsive therapy (ECT);
  14. Patients with renal insufficiency;
  15. Failure to meet standard MRI safety requirements
  16. Electrolytes, blood urea nitrogen, creatinine: outside the normal range (also ruling out renal insufficiency);
  17. Liver function tests above 1.5 times the upper normal;
  18. Corrected QT interval (QTc) interval in EKG above 450 ms or EKG indicative of arrhythmia or cardiac conduction abnormalities;
  19. Diabetes with poor glucose control;
  20. Cardiac disease, bradycardia less than 55 bpm, hypokalemia, congenital prolongation of QT interval or on-going treatment with a medication likely to induce one of these conditions.
  21. Currently in cognitive-behavioral therapy

Primary outcomes:
measure: Effect on PST Reward Learning
timeFrame: administered after scan
measure: Effect on PST Penalty Learning
timeFrame: administered after scan
measure: Effect on Caudate Response to Cues
timeFrame: Scan session
measure: Effect on NAcc Response to Cues
timeFrame: Scan session
measure: Putamen Response to Cues
timeFrame: Scan session
measure: Effect on Caudate Response to Reward
timeFrame: During scan session
measure: Effect on NAcc Response to Reward
timeFrame: During scan session
measure: Effect on Putamen Response to Reward
timeFrame: During scan session
Secondary outcomes:
measure: Effect on Caudate-dACC Connectivity After Reward
timeFrame: During scan session
measure: Effect on NAcc-MCC Connectivity After Reward
timeFrame: During scan session
Other outcomes:
Locations:
city: Belmont
country: United States
facility: McLean Hospital
state: Massachusetts
Study officials:
affiliation: McLean Hospital, Harvard University
name: Diego A Pizzagalli, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Admon R, Kaiser RH, Dillon DG, Beltzer M, Goer F, Olson DP, Vitaliano G, Pizzagalli DA. Dopaminergic Enhancement of Striatal Response to Reward in Major Depression. Am J Psychiatry. 2017 Apr 1;174(4):378-386. doi: 10.1176/appi.ajp.2016.16010111. Epub 2016 Oct 24.
citation: Liu Y, Admon R, Mellem MS, Belleau EL, Kaiser RH, Clegg R, Beltzer M, Goer F, Vitaliano G, Ahammad P, Pizzagalli DA. Machine Learning Identifies Large-Scale Reward-Related Activity Modulated by Dopaminergic Enhancement in Major Depression. Biol Psychiatry Cogn Neurosci Neuroimaging. 2020 Feb;5(2):163-172. doi: 10.1016/j.bpsc.2019.10.002. Epub 2019 Oct 22.